The Impact of the Human Papillomavirus Vaccine on High-Grade Cervical Lesions in Urban and Rural Areas: An Age–Period–Cohort Analysis by Shing, Jaimie Z. et al.
University of Kentucky 
UKnowledge 
Behavioral Science Faculty Publications Behavioral Science 
8-21-2021 
The Impact of the Human Papillomavirus Vaccine on High-Grade 
Cervical Lesions in Urban and Rural Areas: An 
Age–Period–Cohort Analysis 




Marie R. Griffin 
Vanderbilt University 
Rachel S. Chang 
Vanderbilt University 
Staci L. Sudenga 
Vanderbilt University 
See next page for additional authors 
Follow this and additional works at: https://uknowledge.uky.edu/behavsci_facpub 
 Part of the Behavior and Behavior Mechanisms Commons, and the Oncology Commons 
Right click to open a feedback form in a new tab to let us know how this document benefits you. 
Repository Citation 
Shing, Jaimie Z.; Beeghly-Fadiel, Alicia; Griffin, Marie R.; Chang, Rachel S.; Sudenga, Staci L.; Slaughter, 
James C.; Pemmaraju, Manideepthi; Mitchel, Edward F.; and Hull, Pamela C., "The Impact of the Human 
Papillomavirus Vaccine on High-Grade Cervical Lesions in Urban and Rural Areas: An Age–Period–Cohort 
Analysis" (2021). Behavioral Science Faculty Publications. 70. 
https://uknowledge.uky.edu/behavsci_facpub/70 
This Article is brought to you for free and open access by the Behavioral Science at UKnowledge. It has been 
accepted for inclusion in Behavioral Science Faculty Publications by an authorized administrator of UKnowledge. 
For more information, please contact UKnowledge@lsv.uky.edu. 
The Impact of the Human Papillomavirus Vaccine on High-Grade Cervical 
Lesions in Urban and Rural Areas: An Age–Period–Cohort Analysis 
Digital Object Identifier (DOI) 
https://doi.org/10.3390/cancers13164215 
Notes/Citation Information 
Published in Cancers, v. 13, issue 16, 4215. 
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. 
This article is an open access article distributed under the terms and conditions of the Creative 
Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). 
Authors 
Jaimie Z. Shing, Alicia Beeghly-Fadiel, Marie R. Griffin, Rachel S. Chang, Staci L. Sudenga, James C. 
Slaughter, Manideepthi Pemmaraju, Edward F. Mitchel, and Pamela C. Hull 
This article is available at UKnowledge: https://uknowledge.uky.edu/behavsci_facpub/70 
cancers
Article
The Impact of the Human Papillomavirus Vaccine on
High-Grade Cervical Lesions in Urban and Rural Areas: An
Age–Period–Cohort Analysis
Jaimie Z. Shing 1,* , Alicia Beeghly-Fadiel 1, Marie R. Griffin 2, Rachel S. Chang 3, Staci L. Sudenga 1 ,




Beeghly-Fadiel, A.; Griffin, M.R.;
Chang, R.S.; Sudenga, S.L.;
Slaughter, J.C.; Pemmaraju, M.;
Mitchel, E.F.; Hull, P.C. The Impact of
the Human Papillomavirus Vaccine
on High-Grade Cervical Lesions in
Urban and Rural Areas: An
Age–Period–Cohort Analysis. Cancers
2021, 13, 4215. https://doi.org/
10.3390/cancers13164215
Academic Editor: W. Martin Kast
Received: 26 July 2021
Accepted: 18 August 2021
Published: 21 August 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center,
Nashville, TN 37232, USA; alicia.beeghly@vumc.org (A.B.-F.); staci.sudenga@vumc.org (S.L.S.)
2 Department of Health Policy, Vanderbilt University Medical Center, Nashville, TN 37232, USA;
marie.griffin@vumc.org (M.R.G.); manideepthi.pemmaraju@vumc.org (M.P.); ed.mitchel@vumc.org (E.F.M.)
3 School of Medicine, Vanderbilt University, Nashville, TN 37232, USA; rachel.s.chang@vanderbilt.edu
4 Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN 37232, USA;
james.c.slaughter@vumc.org
5 Department of Behavioral Science, University of Kentucky Markey Cancer Center, Lexington, KY 40504, USA;
pam.hull@uky.edu
* Correspondence: Jaimie.shing@nih.gov; Tel.: +1-240-620-0708
Simple Summary: Human papillomavirus (HPV) vaccination disparities between urban and rural
regions may moderate the vaccine’s impact on reducing cervical precancer (CIN2+) and cancer
incidence. We assessed population-level trends in CIN2+ incidence (2008–2018) in urban and rural
areas among Medicaid-enrolled women aged 18–39 years in Tennessee, United States. A sub-group
analysis among women screened for cervical cancer was conducted to control for changing screening
trends. CIN2+ incidence among young women aged 18–20 and 21–24 years, who most likely benefited
from the HPV vaccine, declined similarly between urban and rural areas, although significant declines
began earlier in urban versus rural areas. Our results suggest evidence of HPV vaccine impact
regardless of urbanicity but demonstrate lagged impact in rural areas. These findings emphasize
the importance of reducing barriers to HPV vaccination, particularly in rural areas, to improve the
reduction of cervical precancer and cancer incidence, toward the World Health Organization’s goals
of eliminating cervical cancer.
Abstract: Disparities in human papillomavirus (HPV) vaccination exist between urban (metropolitan
statistical areas (MSAs)) and rural (non-MSAs) regions. To address whether the HPV vaccine’s
impact differs by urbanicity, we examined trends in cervical intraepithelial neoplasia grades 2
or 3 and adenocarcinoma in situ (collectively, CIN2+) incidence in MSAs and non-MSAs among
Tennessee Medicaid (TennCare)-enrolled women aged 18–39 years and among the subset screened
for cervical cancer in Tennessee, United States. Using TennCare claims data, we identified annual age-
group-specific (18–20, 21–24, 25–29, 30–34, and 35–39 years) CIN2+ incidence (2008–2018). Joinpoint
regression was used to identify trends over time. Age–period–cohort Poisson regression models
were used to evaluate age, period, and cohort effects. All analyses were stratified by urbanicity
(MSA versus non-MSA). From 2008–2018, 11,243 incident CIN2+ events (7956 in MSAs; 3287 in
non-MSAs) were identified among TennCare-enrolled women aged 18–39 years. CIN2+ incident
trends (2008–2018) were similar between women in MSAs and non-MSAs, with largest declines
among ages 18–20 (MSA average annual percent change (AAPC): −30.4, 95% confidence interval
(95%CI): −35.4, −25.0; non-MSA AAPC: −30.9, 95%CI: −36.8, −24.5) and 21–24 years (MSA AAPC:
−14.8, 95%CI: −18.1, −11.3; non-MSA AAPC: −15.1, 95%CI: −17.9, −12.2). Significant declines for
ages 18–20 years began in 2008 in MSAs compared to 2010 in non-MSAs. Trends were largely driven
by age and cohort effects. These patterns were consistent among screened women. Despite evidence
of HPV vaccine impact on reducing CIN2+ incidence regardless of urbanicity, significant declines in
CIN2+ incidence were delayed in non-MSAs versus MSAs.
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1. Introduction
The current nonavalent human papillomavirus (HPV) vaccine can prevent up to 90%
of cervical cancer cases [1]. Despite being vaccine-preventable, cervical cancer remains the
fourth most common incident cancer in women worldwide, causing over 300,000 cervical
cancer-related deaths annually [2]. In the United States (US) and other high-income
countries, studies have demonstrated reductions in intermediate endpoints for cervical
cancer, such as high-grade cervical lesions, including cervical intraepithelial neoplasia
(CIN) grades 2 and 3, and adenocarcinoma in situ (together referred to as CIN2+) [3].
In the US, the HPV vaccine is covered for all children up to age 18 years under the
federal Vaccines for Children program. While studies have documented overall declines in
HPV-related adverse health outcomes among younger age groups who were most likely
to have benefited from the introduction of the vaccine, disparities in HPV vaccination
exist between urban and rural geographical regions [4–8], raising concern that the timing
or magnitude of vaccine impact may differ for these populations. Specifically in the
US, HPV vaccine initiation among adolescents aged 13–17 years in urban areas, known
as metropolitan statistical areas (MSAs), increased from 49% to 74% from 2013 to 2019,
compared to 37% to 64% in rural areas (non-MSAs) [7,9]. Despite increasing adolescent
HPV vaccination within urban and rural areas over time, annual vaccination coverage has
significantly lagged behind in rural areas compared to urban areas [7].
Similar geographic disparities have also been demonstrated among adults, with 42%
lower odds of HPV vaccine initiation for adults aged 18–26 years in rural areas compared
to urban areas across eight US states [8]. These geographic differences may be attributed to
rural areas having more barriers to vaccination, including lack of health care access, lack of
knowledge and awareness of HPV and its link to cancer, increased negative community
messaging regarding the vaccine, and more prevalent religious and cultural beliefs that may
not support vaccination [10]. Given these large geographic disparities in both adolescent
and adult HPV vaccination, examining whether urbanicity has modified the vaccine’s
impact on reducing HPV-related outcomes is important for informing HPV vaccination
guidelines and public health interventions to improve vaccination rates.
Low- and middle-resource countries have added barriers to HPV vaccination, in-
cluding lack of vaccine availability due to the high cost of the vaccine, difficulties with
implementing routine adolescent immunization programs, and competing health priori-
ties [11]. Thus, examining trends in HPV-related health outcomes among lower resource
settings, such as rural regions in the US, can provide valuable information on the HPV
vaccine’s impact on reducing HPV-related health outcomes even when vaccination rates
are low.
A few studies have examined trends in HPV-associated health outcomes by urban-
icity [12–15]; of these, most have focused on the vaccine’s impact on reducing anogenital
warts [13–15]. Only one study to date has assessed trends in CIN2+ incidence by urbanicity,
reporting significant declines in CIN2+ incidence from 2008 to 2011 among women aged
21–24 years in both urban and rural counties in Connecticut [12]. However, this study
did not examine CIN2+ trends by urbanicity for other age groups and did not control for
possible changes in cervical cancer screening over time. To better understand the HPV
vaccine’s impact on CIN2+ by urbanicity, we examined temporal trends in CIN2+ incidence,
including age, period, and birth cohort effects, from 2008 through 2018, in urban and rural
areas in Tennessee among (1) women aged 18–39 years enrolled in the Tennessee Medicaid
(TennCare) program and (2) the subset of women who were screened for cervical cancer to
control for changes in screening rates over time.
Cancers 2021, 13, 4215 3 of 15
2. Methods
2.1. Study Population
The Medicaid program is a federal public insurance program in the US that covers low-
income individuals. In the state of Tennessee, the Medicaid program is called TennCare.
We used TennCare billing claims data to identify women aged 18–39 years who were
enrolled in TennCare from 2008 to 2018. For the subset of screened women, we identified
TennCare-enrolled women who were screened for cervical cancer at least once during any
given year using billing codes for:
• an HPV screening examination: International Classification of Diseases 9th revision
(ICD-9) code V73.81 or International Classification of Diseases 10th revision (ICD-10)
code Z11.51; or
• a Papanicolaou test: ICD-9 codes V72.31, V72.32, V76.2, V76.47, 795.06, 91.46, or
ICD-10 codes Z01.411, Z01.419, Z01.42, Z12.4, Z12.72, R87.614, or Current Procedural
Terminology (CPT) codes 88141-88145, 88147-88148, 88150-88158, 88164-88167, 88174-
88175, or Healthcare Common Procedure Coding System codes P3000-P3001, G0101,
G0123-G0124, G0141, G0143-G0145, G0147-G0148, Q0091; or
• an HPV deoxyribonucleic acid (DNA) test: ICD-9 codes 795.05, 795.09, or ICD-10
codes R87.10, R87.820, or CPT codes 87620-87622, 87623-87625.
To examine CIN2+ trends by urbanicity, women with missing data on residence were
excluded. Urbanicity was categorized by county of residence using the MSA definitions
and boundaries set by the US Census Bureau [16]. Urban areas, or MSAs, were counties
with at least one area with a population of at least 50,000 persons, while all other counties
were considered rural areas (non-MSAs) [16]. This study was considered public health
surveillance (i.e., not human research) by the Institutional Review Boards at Vanderbilt
University and the Tennessee Department of Health. This research activity was reviewed
and approved by the Tennessee Department of Finance and Administration Division
of TennCare.
2.2. Incident CIN2+ Event Definition
Incident CIN2+ events, including cervical intraepithelial lesions grades 2 and 3, and
adenocarcinoma in situ, were identified by a validated claims-based model using billing
codes among women with cervical diagnostic procedures who were consecutively enrolled
in TennCare for at least one year from their diagnostic procedure date, as previously
described in detail [17]. Briefly, among women with cervical diagnostic procedures, we
derived predicted probabilities of CIN2+ using billing codes that indicated:
• relevant diagnoses: CIN2+ tissue, non-specific CIN, high-grade squamous intraep-
ithelial lesion cytology, CIN grade 1 tissue, low-grade squamous intraepithelial lesion
cytology, and atypical squamous cells of undetermined significance; and/or
• cervical screening: HPV screening examination, Papanicolaou test, and HPV DNA
test; and/or
• relevant procedures: cervical treatment procedures and cervical or vaginal biopsies.
All corresponding billing codes have been provided previously [17]. For the subset of
women who were screened for cervical cancer, CIN2+ events were counted if the screening
date was within one year of the diagnostic procedure date. Incident CIN2+ events were
model-identified events that did not have another CIN2+ event for at least one year prior
to the diagnostic procedure date. Incident CIN2+ events in MSAs and non-MSAs were
only counted if the woman resided in an MSA or non-MSA county, respectively, on the
date of their cervical diagnostic procedure.
2.3. Denominator and Rates
Annual person-years for each age group (18–20, 21–24, 25–29, 30–34, and 35–39 years)
were estimated by counting the total number of women who were enrolled in TennCare
on July 1 of each year with at least one year of consecutive enrollment. For example,
Cancers 2021, 13, 4215 4 of 15
total person-years for 2008 comprised TennCare-enrolled women who were continuously
enrolled between 1 July 2007, and 1 July 2008. Screened person-years included the subset
of total women who had a least one cervical cancer screening code during the year prior to
July 1 of each year. Only women residing in an MSA or non-MSA county on July 1 of each
year were counted toward the person-time estimation for MSA and non-MSA populations,
respectively. Annual CIN2+ incidence rates per 100,000 person-years were calculated by
dividing the total number of women meeting the incident CIN2+ event definition by the
estimated person-time for each year and age group among all women and those residing
in MSA and non-MSA counties and then multiplying by 100,000.
2.4. Joinpoint Trend Analyses
We identified CIN2+ incident trends and significant changes in CIN2+ trends (i.e.,
changes in slope) over time using the Joinpoint Desktop Software version 4.5.01 (National
Cancer Institute, Bethesda, MD, USA), which calculated average percent changes (APCs,
beta coefficients for each trend) and average annual percent changes (AAPCs, weighted
averages of APCs) from 2008 to 2018, by urbanicity [18]. Using grid search and permutation
tests, we allowed for a maximum of two joinpoints detected per model with uncorrelated
errors to determine the best fit log-linear models. Using a two-sided alpha threshold of
0.05, 95% confidence intervals (CI) that excluded 0 were considered statistically significant.
2.5. Age–Period–Cohort Analyses
Age, period, and birth cohort effects were evaluated using the Clayton and Schiffler
modeling approach for age–period–cohort analyses [19]. Age effects are differences in
biological or social processes linked to maturation, such as age-associated risk factors for
CIN2+ (e.g., number of lifetime sexual partners, condom use, and prevalence of high-risk
HPV-type infections). Period effects refer to environmental factors that impact all ages.
Cohort effects are historical differences between groups who were born in different eras,
such as the availability of the HPV vaccine for younger ages and ineligibility for older ages
when the vaccine was first introduced.
The Clayton and Schiffler model building process begins with an age model, then adds
a “drift” parameter (i.e., the sum of the linear period and cohort effects) [19]. Derivatives
of the drift parameter are estimated and regressed on period and cohort to estimate their
effects on trends [19]. The following sub models were derived: (1) age, (2) age–drift, (3) age–
cohort, (4) age–period, and (5) age–period–cohort. The general multiplicative formula
for the age–period–cohort models was based on Poisson regression to derive incidence
rates (log(λ |A, P, C)) at age (A) in a period (P) for persons in birth cohort (C) using the
following equation:
log(λ |A, P, C)): f (A) + g(P) + h(C), (1)
where A, P, and C represent the mean age, period, and birth cohort for the observational
units, respectively, and f, g, and h, represent the functions for each effect [20]. Synthetic
birth cohort groups were calculated by subtracting the midpoint of each age group (18–20,
21–24, 25–29, 30–34, and 35–39 years) from each one-year period (2008, 2009, 2010, 2011,
2012, 2013, 2014, 2015, 2016, 2017, and 2018).
Because of the linear dependency between age, period, and cohort effects (C=P-A),
the simultaneous linear effects of all three effects cannot be estimated; therefore, any
parameterization of the age–period–cohort model included two fixed levels and one slope
among the three functions [19]. We parameterized our models based on the maximum
likelihood of the age–period–cohort model, considering age effects as incidence rates for
the reference period (2008) and period effects as rate ratios relative to the reference period
(2008) [20]. Cohort effects were constrained to be 0 on average with 0 slope and therefore
interpreted as rate ratios relative to the age–period predictions (i.e., residual rate ratios) [20].
We estimated annual percent changes (EAPC), or the overall linear trends, from the net
drift in the age–drift models.
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Model goodness-of-fit was examined using residual deviance statistics. Using the
Clayton and Schiffler approach [19], model fit was assessed for each sub model, comparing
each iterative model to the primary model of age alone by sequentially adding cohort and
period effects to determine whether these added parameters significantly improved model
fit. Then, model fit was deductively assessed by iteratively removing parameters and
testing whether this significantly reduced model fit. We tested for significant differences in
residual deviance of each pairwise comparison using chi-squared tests. All age–period–
cohort analyses were conducted using the apc.fit function from the Epi package in R
(version 3.6.2) [20]. p-values <0.05 were considered statistically significant.
3. Results
3.1. Age-Specific Trends in CIN2+ Incidence
Between 2008 and 2018, we identified 7956 incident CIN2+ events in MSA counties,
compared to 3287 incident CIN2+ events in non-MSA counties (total: 11,243) (Table 1).
Table 1. Annual age-group-specific CIN2+ incidence per 100,000 person-years among all women enrolled in Tennessee
Medicaid and the subset of women screened for cervical cancer by urbanicity, 2008–2018.
Age (yrs) MSA Residence Non-MSA Residence
18–20 21–24 25–29 30–34 35–39 18–20 21–24 25–29 30–34 35–39
Among All Women
Total PY 279,140 308,959 412,173 380,147 318,804 109,144 114,431 148,471 138,304 121,270
CIN2+ Events 640 1909 2664 1713 1030 312 847 1083 690 355
Year
2008 720.5 1098.7 771.7 462.4 352.2 720.5 1471.7 1076.1 557.1 292.7
2009 669.3 946.9 869.1 529.2 420.0 755.5 1267.8 1056.5 779.7 360.1
2010 477.8 1113.3 827.0 584.6 362.9 758.7 1200.4 1061.4 689.1 436.0
2011 289.1 887.2 706.2 542.1 435.4 390.8 1110.6 895.0 561.9 251.2
2012 284.0 808.0 779.5 521.1 340.0 323.4 913.9 813.5 511.4 311.3
2013 133.7 692.3 683.4 468.2 323.2 190.6 851.0 959.4 568.1 270.1
2014 92.7 441.5 574.8 422.4 295.5 106.7 452.3 549.0 443.8 203.7
2015 49.9 369.2 513.7 397.5 275.4 84.7 476.1 622.0 450.1 277.4
2016 12.0 276.6 566.1 349.2 293.4 15.5 376.1 532.6 398.3 220.1
2017 14.4 318.4 518.8 407.6 291.9 37.0 281.0 460.1 435.4 276.2
2018 26.3 259.2 534.5 422.5 281.1 19.0 380.1 507.5 363.3 366.6
Among Women Screened for Cervical Cancer
Total PY 75,181 123,842 153,229 122,514 88,209 29,593 44,909 51,356 40,178 30,174
CIN2+ Events 616 1798 2521 1591 944 305 783 1001 648 333
Year
2008 1497.6 2081.3 1702.6 1221.0 1080.7 1456.2 2660.4 2411.1 1601.1 1035.2
2009 1451.8 1787.5 1867.3 1317.5 1206.8 1603.8 2319.1 2239.1 1979.6 1170.1
2010 1106.1 2170.3 1823.2 1377.9 1033.4 1663.3 2313.6 2315.5 1872.1 1462.7
2011 696.1 1734.7 1569.5 1373.9 1281.5 1015.4 2216.6 2169.7 1583.3 815.7
2012 892.1 1695.8 1758.4 1385.4 1060.7 1011.2 1814.1 2023.1 1470.2 1104.3
2013 506.9 1547.3 1683.0 1277.9 955.4 760.8 1914.8 2497.7 1787.3 959.9
2014 401.7 1118.5 1495.3 1223.7 1054.9 472.2 1151.0 1475.1 1562.5 782.5
2015 288.5 999.2 1474.9 1300.1 1016.9 452.7 1409.1 1899.6 1770.4 1088.4
2016 58.5 822.7 1626.2 1137.2 1079.2 107.4 1046.9 1718.0 1418.0 980.7
2017 99.9 835.8 1500.3 1298.8 1016.1 258.1 748.3 1409.6 1651.7 1089.7
2018 178.8 739.8 1627.1 1393.0 1041.0 159.1 1193.5 1453.7 1191.6 1561.0
CIN2+: cervical intraepithelial neoplasia grades 2 and 3, and adenocarcinoma in situ; MSA: metropolitan statistical area; PY: person-years.
Of the total number of events, 10,540 (94%) women (7470 MSA; 3070 non-MSA) had a
cervical screening code identified in the year prior to their incident event. Among women
residing in MSAs, CIN2+ incidence significantly declined from 2008 to 2018 for those aged
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18–20 years (AAPC: −30.4; 95% CI: −35.4, −25.0), 21–24 years (AAPC: −14.8; 95% CI:
−18.1, −11.3), 25-29 years (AAPC: −5.3; 95% CI: −7.1, -3.6), and 35–39 years (AAPC: −3.9;
95% CI: −5.8, −1.9) (Table 2, Figure 1).
Table 2. Average annual percent changes in age-group-specific CIN2+ incidence among all women enrolled in Tennessee
Medicaid and the subset of women screened for cervical cancer, by urbanicity, 2008–2018.
MSA Residence Non-MSA Residence
Age, Years AAPC 1 95% CI AAPC 1 95% CI
Among All Women
18–20 −30.4 * −35.4, −25.0 −30.9 * −36.8, −24.5
21–24 −14.8 * −18.1, −11.3 −15.1 * −17.9, −12.2
25–29 −5.3 * −7.1, −3.6 −8.8 * −11.3, −6.3
30–34 −0.8 −2.6, 1.1 −6.2 * −8.5, −3.8
35–39 −3.9 * −5.8, −1.9 −1.5 −6.1, 3.2
Among Women Screened for Cervical Cancer
18–20 −21.1 * −26.1, −15.8 −19.8 * −26.5, −12.4
21–24 −10.4 * −13.2, −7.6 −10.0 * −12.7, −7.1
25–29 −2.6 * −2.9, −0.2 −4.9 * −7.5, −2.3
30–34 1.3 −2.4, 5.2 −2.5 −5.0, 0.1
35–39 −1.1 −2.7, 0.5 1.1 −3.4, 5.8
AAPC: average annual percent change; CI: confidence interval; CIN2+: cervical intraepithelial neoplasia grades 2 and 3, and adenocarcinoma
in situ; MSA: metropolitan statistical area. 1 Average annual percent changes are weighted averages of annual percent changes from 2008 to
2018. * Asterisks indicate statistical significance (p < 0.05).
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Figure 1. Annual CIN2+ incidence per 100,000 person-years among all women enrolled in Tennessee Medicaid and the
subset of women screened for cervical cancer who resided in MSAs versus non-MSAs aged: (a) 18–20 years; (b) 21–24 years;
(c) 25–29 years; (d) 30–34 years; (e) 35–39 years. CIN2+: cervical intraepithelial neoplasia grades 2 and 3 and adenocarcinoma
in situ; MSA: metropolitan statistical area; PY: person-years.
However, after restricting to screened women, declines in CIN2+ were only observed
for the youngest three age groups. Among women residing in non-MSAs, CIN2+ incidence
significantly declined for those aged 18–20 years (AAPC: −30.9; 95% CI: −36.8, −24.5),
21–24 years (AAPC: −17.9, 95% CI: −17.9, −12.2), 25–29 years (AAPC: −8.8; 95% CI: −11.3,
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−6.3), and 30–34 years (AAPC: −6.2; 95% CI: −8.5, −3.8). Again, after restricting to women
who were screened for cervical cancer, significant declines were only observed for the three
youngest age groups.
Several Joinpoint-detected inflections (e.g., time points where there are significant
changes in slopes across time periods) were identified (Table 3). Among women residing in
MSAs, inflections were only observed for those aged 30–34 years, with significant increases
in CIN2+ incidence from 2008 to 2010 (APC: 13.3; 95% CI: 1.5, 26.4), followed by significant
decreases from 2010–2016 (APC: −8.0; 95% CI: −9.9, −6.1). This pattern was mirrored,
yet less pronounced and non-significant, among screened women aged 30–34 years who
resided in MSAs. Among women residing in non-MSAs, an inflection was only observed
among those aged 18–20 years, with stable trends from 2008 to 2010, followed by significant
declines in CIN2+ incidence from 2010 to 2018 (APC: −37.0; 95% CI: −43.4, −29.9). This
pattern was similar to that of screened women aged 18–20 years who resided in non-MSAs.
Table 3. Annual percent changes in age-group-specific CIN2+ incidence among all women enrolled in Tennessee Medicaid
and the subset of women screened for cervical cancer, by urbanicity, 2008–2018.











18–20 – 2008–2018 −30.4 * −35.4, −25.0 2010 2008–2010 0.2 −29.4, 42.4
2010–2018 −37.0 * −43.4, −29.9
21–24 – 2008–2018 −14.8 * −18.1, −11.3 – 2008–2018 −15.1 * −17.9, −12.2
25–29 – 2008–2018 −5.3 * −7.1, −3.6 – 2008–2018 −8.8 * −11.3, −6.3
30–34 2010 2008–2010 13.3 * 1.5, 26.4 – 2008–2018 −6.2 * -8.5, −3.8
2016 2010–2016 −8.0 * −9.9, −6.1
2016–2018 9.0 −0.2, 19.2
35–39 – 2008–2018 −3.9 * −5.8, −1.9 – 2008–2018 −1.5 −6.1, 3.2
Among Women Screened for Cervical Cancer
Age, Years
18–20 – 2008–2018 −21.1 * −26.1, −15.8 2010 2008–2010 4.5 −26.2, 47.8
2010–2018 −24.9 * −32.5, −16.5
21–24 – 2008–2018 −10.4 * −13.2, −7.6 – 2008–2018 −10.0 * −12.7, −7.1
25–29 – 2008–2018 −2.6 * −2.9, −0.2 – 2008–2018 −4.9 * −7.5, −2.3
30–34 2010 2008–2010 7.5 −13.3, 33.3 – 2008–2018 −2.5 −5.0, 0.1
2016 2010–2016 −2.8 −6.7, 1.2
2016–2018 8.4 −9.4, 29.7
35–39 – 2008–2016 −1.1 −2.7, 0.5 – 2008–2018 1.1 −3.4, 5.8
APC: annual percent change; CI: confidence interval; CIN2+: cervical intraepithelial neoplasia grades 2 and 3 and adenocarcinoma in situ;
MSA: metropolitan statistical area. 1 Annual percent changes were determined by the β-coefficient of the best fit log-linear model using a
permutation test and Poisson variance for each time period detected by Joinpoint. * Asterisks indicate statistical significance (p < 0.05).
3.2. Descriptive Age, Period, Cohort Effects
Women residing in MSAs showed similarities in CIN2+ incidence rates by period and
birth cohort compared to women residing in non-MSAs (Figure 2). Patterns were similar
in that young women aged 18–20, 21–24, and 25–29 years had higher CIN2+ incidence
at baseline (2008) compared to older women, with the highest rates among women aged
21–24 years (1098.7/100,000 person-years in MSAs and 1471.7/100,000 person-years in
non-MSAs). The most drastic changes in CIN2+ rates were in the youngest age group
(18–20 years) from 720.5/100,000 person-years in 2008 to 26.3/100,000 person-years in 2018
among MSAs and 720.5/100,000 person-years in 2008 to 19.0/100,000 person-years in 2018
among non-MSAs. Rates of decline varied by age group. For younger age groups, women
who were born later had lower CIN2+ incidence rates. This pattern was also observed in
screened women (Figure 3).
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Figure 2. Age-group-specific CIN2+ incidence per 100,000 person-years by period and birth cohort among all women
enrolled in Tennessee Medicaid. I 2+: cervical intraepithelial neoplasia grades 2 and 3 and adenocarcinoma in situ; MSA:
m tropolita statistical area.
3.3. Age, Period, and Cohort Effects in Poisson Regression Models
Age–period–cohort Poisson regression models indicated decreasing CIN2+ incidence
from 2008 to 2018 for both MSAs (EAPC: 0.90%/year) and non-MSAs (EAPC: 0.89%/year)
(Table 4). Significant improvements in model fit were found when adding drift (i.e., the
overall linear trend in CIN2+ incidence), period, and cohort effects (p < 0.001). The best-
fitting model included all three effects (age–period–cohort), indicated by the lowest residual
deviance, for women residing in MSAs (residual deviance: 662.6) and non-MSAs (residual
deviance: 410.9). Model comparisons demonstrated notably larger cohort than period
effects (change in deviance for nonlinear cohort effects versus nonlinear period effects:
562.3 versus 51.3 [MSA], 203.5 versus 19.8 [non-MSA]).
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Figure 3. Age-group-specific CIN2+ incidence per 100,000 person-years by period and birth cohort among the subset of
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Figure 3. Age-group-specific CIN2+ incidence per 100,000 person-years by period and birth cohort among the subset of
women enrolled in Tennessee Medicaid who were screened for cervical cancer. CIN2+: cervical intraepithelial neoplasia
grades 2 and 3 and adenocarcinoma in situ; MSA: metropolitan statistical area.
Table 4. Age–period–cohort models for CIN2+ incidence among all women enrolled in Tennessee Medicaid and the subset











Deviance p-Value EAPC (95% CI)
Among All Women
MSA 0.90(0.90, 0.91)
1. Age 238 2006.75 – – – –
2. Age–Drift 237 1295.52 <0.001 2 versus 1 Trend (d ift) 1 711.23 <0.001
3. Age–Cohort 234 733.25 <0.001 3 v rsus 2 Nonlinear cohorteffect 3 562.27 <0.001
4. Age–Period 234 1244.25 <0.001 4 versus 2 Nonlinear periodeffect 3 51.27 <0.001
5. Age–Period–
Cohort 231 662.64 <0.001 5 versus 3
Period effect adjusted
for cohort 3 70.60 <0.001
5 versus 4 Cohort effect adjustedfor period 3 581.60 <0.001












Deviance p-Value EAPC (95% CI)
Non-MSA 0.89(0.88, 0.90)
1. Age 238 1080.50 – – – –
2. Age–Drift 237 639.10 <0.001 2 versus 1 Trend (drift) 1 441.40 <0.001
3. Age–Cohort 234 435.57 <0.001 3 versus 2 Nonlinear cohorteffect 3 203.53 <0.001
4. Age–Period 234 619.29 <0.001 4 versus 2 Nonlinear periodeffect 3 19.81 <0.001
5. Age–Period–
Cohort 231 410.92 <0.001 5 versus 3
Period effect adjusted
for cohort 3 24.66 <0.001
5 versus 4 Cohort effect adjustedfor period 3 208.37 <0.001
Among Women Screened for Cervical Cancer
MSA 0.96(0.95, 0.96)
1. Age 238 891.14 – – – –
2. Age–Drift 237 729.89 <0.001 2 versus 1 Trend (drift) 1 161.25 <0.001
3. Age–Cohort 234 463.58 <0.001 3 versus 2 Nonlinear cohorteffect 3 266.30 <0.001
4. Age–Period 234 714.29 <0.001 4 versus 2 Nonlinear periodeffect 3 15.60 0.001
5. Age–Period–
Cohort 231 436.61 <0.001 5 versus 3
Period effect adjusted
for cohort 3 26.97 <0.001
5 versus 4 Cohort effect adjustedfor period 3 277.68 <0.001
Non-MSA 0.94(0.93, 0.96)
1. Age 238 499.55 – – – –
2. Age–Drift 237 383.80 <0.001 2 versus 1 Trend (drift) 1 1115.75 <0.001
3. Age–Cohort 234 301.08 0.002 3 versus 2 Nonlinear cohorteffect 3 82.72 <0.001
4. Age–Period 234 380.60 <0.001 4 versus 2 Nonlinear periodeffect 3 3.20 0.362
5. Age–Period–
Cohort 231 296.86 0.002 5 versus 3
Period effect adjusted
for cohort 3 4.21 0.239
5 versus 4 Cohort effect adjustedfor period 3 83.73 <0.001
CI: confidence interval; CIN2+: cervical intraepithelial neoplasia grades 2 and 3 and adenocarcinoma in situ; df: degrees of freedom; EAPC:
estimated annual percent change; MSA: metropolitan statistical area.
Among screened women, age–cohort and age–period–cohort models had similar
goodness-of-fit, with slightly better fit for age–period–cohort models (residual deviance
for age–cohort versus age–period–cohort: 463.6 versus 436.6 (MSA), 301.1 versus 296.9
(non-MSA)) (Table 4).
Among screened women residing in MSAs, cohort effects were larger than period
effects (change in deviance for nonlinear cohort effects versus nonlinear period effects:
266.3 versus 15.6). Among screened women residing in non-MSAs, nonlinear period effects
and period effects adjusted for cohort effects were not significant (p > 0.05); however, the
drift, nonlinear cohort effects, and cohort effects adjusted for period effects were significant
(p < 0.001).
For both women residing in MSAs and non-MSAs, age effects showed increasing
CIN2+ incidence with increasing age among younger women until a peak of around age
27 years, followed by plateauing or decreasing CIN2+ incidence with increasing age among
older women (Figure 4). Cohort effects demonstrated that women born between 1970 to
1988 experienced higher CIN2+ incidence with later years of birth, while women born
after 1988 experienced lower CIN2+ incidence with later years of birth. Period effects
demonstrated decreasing CIN2+ incidence from 2009 to the mid-2010s, and then a mild
increasing curvature in the late 2010s. For screened women, CIN2+ incidence had similar,
yet less steep and prominent, period effect patterns compared to all women.
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4. Discussion
We examined temporal trends in CIN2+ incidence, including age, period, and cohort
effects, among TennCare-enrolled women from 2008 to 2018, by urbanicity. In both MSAs
and non-MSAs, our results demonstrated declining trends in CIN2+ incidence among
women aged 18–39 years from 2008 onward, with the most drastic declines among young
women aged 18–20 years and 21–24 years. As shown by the significant cohort and age
effects, declines in CIN2+ were likely because of the HPV vaccine’s introduction in 2006
and the Advisory Committee on Immunization Practices’ recommendations for adoles-
cent HPV vaccination, as well as changes in cervical cancer screening and management
recommendations and aggressiveness of approach [21–23]. Although patterns and rates of
decline in CIN2+ incidence were similar between women residing in MSAs and non-MSAs,
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significant declines were delayed until 2010 for women residing in non-MSAs, unlike in
MSAs, which began in 2008. After restricting our analyses to women screened for cervical
cancer to control for the confounding effects of changing screening rates over time, HPV
vaccine impact was still evident, regardless of urbanicity.
Our age–period–cohort analyses indicated that trends in CIN2+ incidence were largely
driven by cohort effects (i.e., historical factors associated with birth year) and age effects
(i.e., social and biological variations associated with age), even after adjusting for period
effects. Specifically, young women in more recent generations had lower rates of CIN2+
compared to young women born earlier. Cohort effects were likely due to generational
differences in vaccine eligibility, vaccination behaviors, and screening recommendations
in the US. When the Food and Drug Administration approved the first quadrivalent HPV
vaccine in 2006 for females aged 9–26 years [21], older women were ineligible for the
vaccine. Further, cervical cancer screening guidelines have changed. Historically in the
US, screening was recommended within three years after sexual debut or at age 21 years
(whichever occurred first); however, in 2012, screening in women younger than 21 years
was no longer recommended, protecting adolescents and young women from unnecessary
invasive gynecologic procedures that could increase their risk for cervical damage [23].
Changes in screening guidelines may have contributed to decreases in CIN2+ detection
among younger women. Further, updated guidelines for the aggressiveness of follow-up
approaches, such as frequency of screening, may have also contributed to less frequent
screening and fewer colposcopies and biopsies to detect CIN2+ in screened women [23].
Our finding of significant age effects may be explained by age-associated social and
biological factors regarding the HPV vaccine. Among age-eligible adults aged 18–26 years,
HPV vaccination coverage in the US has been historically low, ranging from 22.1% to 39.9%
for initiation and 13.8% to 21.5% for completion from 2013–2018 [24]. Additionally, HPV
vaccination in women aged over 26 years may be less effective among those who have
already been infected with HPV genotypes covered by the vaccine, creating biological
barriers to preventing CIN2+ in this age group.
For urbanicity-stratified CIN2+ incidence by age group over time, we found similar
patterns and evidence of HPV vaccine impact on reducing CIN2+ incidence in both MSAs
and non-MSAs, despite varying HPV vaccination coverage by urbanicity. In Tennessee
from 2016 to 2019, HPV vaccination in MSAs ranged from 66% to 69% for initiation and
46% to 47% for completion, compared to 46% to 53% for initiation and 25% to 34% for
completion in non-MSAs [9]. A prior study in Connecticut also reported significant declines
in CIN2+ incidence among young women in both urban and rural counties [12]. While
HPV vaccination coverage rates are lower in rural communities than in urban communities,
our results still demonstrated significant declines in CIN2+ in urban and rural settings.
Additionally, despite varying HPV vaccination rates in urban and rural areas, a global-
based meta-analysis reported similar genital HPV infection prevalence in urban (10%)
and rural (11%) areas after the introduction of the HPV vaccine [25], suggesting that HPV
infection rates are comparable regardless of urbanicity. This finding is corroborated by
our prior work among TennCare-enrolled women, showing similar age-group-specific
anogenital wart incidence, an HPV-associated outcome, by urbanicity [13].
Among women who were screened for cervical cancer, HPV vaccine impact was
still evident in MSAs and non-MSAs, with similar declining CIN2+ incidence in young,
screened women (aged 18–20 and 21–24 years) residing in MSAs and non-MSAs. However,
in MSAs, significant declines were observed in screened women aged 25–29 years, while
declines in non-MSAs for this age group were not significant. This may be due to improved
accessibility of HPV vaccination in urban centers upon first release. Delays in HPV vac-
cination access and distribution within non-MSAs due to lack of healthcare sites, limited
transportation, or other barriers may have contributed to a smaller initial impact of the
HPV vaccine. However, similar declines in CIN2+ incidence in both MSAs and non-MSAs
for younger cohorts indicate that non-MSAs were able to overcome initial barriers to HPV
vaccination to have a comparable vaccine impact to MSAs. Further, age, period, and cohort
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effects were all significant among screened women residing in MSAs, while only age and
cohort effects were significant for those residing in non-MSAs. However, because our
sample size for women residing in MSAs was roughly double that of non-MSAs, we cannot
rule out the possibility that differences between MSAs and non-MSAs were also due to
differences in power and sample size.
Our study has limitations. The study represents a unique population of Tennessee
Medicaid women; thus, results may not be generalizable to other geographical regions
or to populations of higher socioeconomic status. For instance, Medicaid populations
have very low cervical cancer screening rates compared to the general US population [26].
Additionally, due to the limitations of other variables that could potentially be associated
with CIN2+ in the TennCare database, such as race/ethnicity and income level [27], our
results did not consider these factors. Specifically, women of Black race and those with
higher levels of poverty have been shown to have higher CIN2+ rates [27]; thus, these
factors may impact CIN2+ trends by urbanicity. Furthermore, because this is an ecologic
study, we were unable to examine individual-level vaccination data, but instead were
able to account for both direct and indirect effects of the HPV vaccine. Lastly, we cannot
exclude the likelihood that some of the variations in CIN2+ trends by urbanicity were due
to differences in sample size between MSAs and non-MSAs, especially after restricting to
women who were screened for cervical cancer.
Our study has notable strengths. This is the first study to describe CIN2+ incident
trends by urbanicity using a validated claims-based model, demonstrating the applicability
of utilizing claims data for CIN2+ surveillance research. Examining population-based
CIN2+ trends in the US is costly and limited to populations with adequate surveillance of
cervical biopsies through the New Mexico HPV Pap Registry [28] and the HPV Vaccine
Impact Monitoring Project [29]. Utilizing claims data can be a more efficient way to monitor
HPV vaccine impact; we were able to leverage TennCare claims data to detect vaccine
impact on reducing CIN2+ incidence among Tennessee Medicaid enrollees, regardless
of urbanicity. Further, this is the first US study to examine secular time trends in CIN2+
incidence using age–period–cohort models. Prior studies examining HPV vaccine impact
on CIN2+ incidence have focused on evaluating overall linear trends using Joinpoint or
pre-to-post vaccine era CIN2+ incidence using incidence rate ratios. We expand upon
these prior studies by attempting to disentangle age, period, and cohort effects on CIN2+
trends using age–period–cohort models. However, due to the linear dependency of all
three effects, the magnitude of each effect cannot be entirely isolated. Finally, our study has
a large overall sample size, increasing the power of the results and reinforcing the validity
of our findings. Given the power and unique low socioeconomic status of our Tennessee
Medicaid study population, results may be translated to other low-income populations,
particularly lower- and middle-resource countries, which are historically underrepresented,
have a higher incidence of cervical cancer, and have increased barriers to cervical cancer
screening. Greater insight into these understudied populations can be utilized to reduce
socioeconomic disparities in cervical cancer, adding to the World Health Organization’s
“90–70–90” global strategy to accelerate the elimination of cervical cancer, which includes
2030 targets for 90% of girls aged <15 years who are up-to-date on their HPV vaccination,
70% of women who are screened for cervical cancer by age 35 years, 90% of identified
cervical precancers treated, and 90% of invasive cervical cancers managed [30].
5. Conclusions
In summary, we demonstrated significant declines in CIN2+ incidence in both MSAs
and non-MSAs among TennCare-enrolled women, particularly in younger women who
likely benefited from the HPV vaccine. CIN2+ trends were mostly driven by age and
cohort effects, but effects in non-MSAs were delayed compared to MSAs, suggesting an
impact of lower vaccination rates and delayed increases in vaccination in non-MSAs. These
results emphasize the importance of reducing barriers to HPV vaccination in lower resource
settings, such as rural regions, to promote cervical cancer elimination.
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